Evaluation of extracellular subviral particles of dengue virus type 2 and Japanese encephalitis virus produced by Spodoptera frugiperda cells for use as vaccine and diagnostic antigens

Clinical and Vaccine Immunology

Volumn 17, Issue 10, 2010, Pages 1560-1566

  Kuwahara, Miwa ^a   Konishi, Eiji ^a,b  

^a KOBE UNIVERSITY   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ELISARTAN; ENVELOPE PROTEIN; MEMBRANE PROTEIN; PROTEIN PREMEMBRANE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; DENGUE; DENGUE VIRUS 2; GENETIC TRANSFECTION; IN VITRO STUDY; INSECT CELL; JAPANESE ENCEPHALITIS; LEPIDOPTERA; MALE; MOUSE; NONHUMAN; PREVENTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CELL LINE; DENGUE VACCINES; DENGUE VIRUS; ENCEPHALITIS VIRUS, JAPANESE; ENZYME-LINKED IMMUNOSORBENT ASSAY; JAPANESE ENCEPHALITIS VACCINES; MALE; MICE; MICE, INBRED ICR; RECOMBINANT PROTEINS; SPODOPTERA; VACCINES, DNA; VACCINES, SYNTHETIC; VACCINES, VIROSOME; VIROSOMES;

EID: 77957866988     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00087-10     Document Type: Article

References (57)

1. Altmann, F., E. Staudacher, I. B. Wilson, and L. März. 1999. Insect cells as hosts for the expression of recombinant glycoproteins. Glycoconj. J. 16:109-123. (Pubitemid 29472137)
2. Babu, J. P., P. Pattnaik, N. Gupta, A. Shrivastava, M. Khan, and P. V. Lakshmana Rao. 2008. Immunogenicity of a recombinant envelope domain III protein of dengue virus type-4 with various adjuvants in mice. Vaccine 26:4655-4663.
3. Bharati, K., and S. Vrati. 2006. Japanese encephalitis: development of new candidate vaccines. Expert Rev. Anti Infect. Ther. 4:313-324.
4. Cuzzubbo, A. J., T. P. Endy, A. Nisalak, S. Kalayanarooj, D. W. Vaughn, S. A. Ogata, D. E. Clements, and P. L. Devine. 2001. Use of recombinant envelope proteins for serological diagnosis of dengue virus infection in an immunochromatographic assay. Clin. Diagn. Lab. Immunol. 8:1150-1155.
5. Davis, B. S., G. J. Chang, B. Cropp, J. T. Roehrig, D. A. Martin, C. J. Mitchell, R. Bowen, and M. L. Bunning. 2001. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J. Virol. 75:4040-4047.
6. Douris, V., L. Swevers, V. Labropoulou, E. Andronopoulou, Z. Georgoussi, and K. Iatrou. 2006. Stably transformed insect cell lines: tools for expression of secreted and membrane-anchored proteins and high-throughput screening platforms for drug and insecticide discovery. Adv. Virus Res. 68:113-156.
7. Etemad, B., G. Batra, R. Raut, S. Dahiya, S. Khanam, S. Swaminathan, and N. Khanna. 2008. An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes. Am. J. Trop. Med. Hyg. 79:353-363.
8. Ge, F. F., Y. F. Qiu, X. Y. Gao, Y. W. Yang, and P. Y. Chen. 2006. Fusion expression of major antigenic segment of JEV E protein-hsp70 and the identification of domain acting as adjuvant in hsp70. Vet. Immunol. Immunopathol. 113:288-296.
9. Gentry, M. K., E. A. Henchal, J. M. McCown, W. E. Brandt, and J. M. Dalrymple. 1982. Identification of distinct antigenic determinants on dengue- 2 virus using monoclonal antibodies. Am. J. Trop. Med. Hyg. 31:548-555.
10. Gubler, D. J., G. Kuno, and L. Markoff. 2007. Flaviviruses, p 1153-1252. In D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Straus (ed.), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
11. Halstead, S. B. 2007. Dengue. Lancet 370:1644-1652.
12. Halstead, S. B., and D. W. Vaughn. 2008. Dengue vaccines, p. 1155-1161. In S. A. Plotkin, W. A. Orenstein, and P. A. Offit (ed.), Vaccines, 5th ed. Saunders Elsevier, Maryland Heights, MO.
13. Halstead, S. B., and J. Jacobsen. 2008. Japanese encephalitis vaccines, p 311-352. In S. A. Plotkin, W. A. Orenstein, and P. A. Offit (ed.), Vaccines, 5th ed. Saunders Elsevier, Maryland Heights, MO.
14. Henchal, E. A., J. M. McCown, D. S. Burke, M. C. Seguin, and W. E. Brandt. 1985. Epitopic analysis of antigenic determinants on the surface of dengue-2 virions using monoclonal antibodies. Am. J. Trop. Med. Hyg. 34:162-169.
15. Hunt, A. R., C. B. Cropp, and G. J. Chang. 2001. A recombinant particulate antigen of Japanese encephalitis virus produced in stably-transformed cells is an effective noninfectious antigen and subunit immunogen. J. Virol. Methods 97:133-149.
16. Igarashi, A. 2002. Control of Japanese encephalitis in Japan: immunization of humans and animals, and vector control. Curr. Top. Microbiol. Immunol. 267:139-152.
17. Ikonomou, L., Y. J. Schneider, and S. N. Agathos. 2003. Insect cell culture for industrial production of recombinant proteins. Appl. Microbiol. Biotechnol. 62:1-20.
18. Imoto, J., and E. Konishi. 2005. Needle-free jet injection of a mixture of Japanese encephalitis DNA and protein vaccine in a murine model. Viral Immunol. 18:205-212.
19. Imoto, J., and E. Konishi. 2007. Dengue tetravalent DNA vaccine increases its immunogenicity in mice when mixed with a dengue type 2 subunit vaccine or an inactivated Japanese encephalitis vaccine. Vaccine 25:1076-1084.
20. Ishikawa, T. 2005. Development of new Japanese encephalitis vaccine. Nippon Rinsho 63:2133-2137. (In Japanese.)
21. Ishikawa, T., and E. Konishi. 2006. Mosquito cells infected with Japanese encephalitis virus release slowly-sedimenting hemagglutinin particles in association with intracellular formation of smooth membrane structures. Microbiol. Immunol. 50:211-223.
22. Ishikawa, T., T. Takasaki, I. Kurane, S. Nukuzuma, T. Kondo, and E. Konishi. 2007. Co-immunization with West Nile DNA and inactivated vaccines provides synergistic increases in their immunogenicities in mice. Microbes Infect. 9:1089-1095.
23. Kelly, E. P., J. J. Greene, A. D. King, and B. L. Innis. 2000. Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice. Vaccine 18:2549-2559.
24. Kojima, A., A. Yasuda, H. Asanuma, T. Ishikawa, A. Takamizawa, K. Yasui, and T. Kurata. 2003. Stable high-producer cell clone expressing virus-like particles of the Japanese encephalitis virus E protein for a second-generation subunit vaccine. J. Virol. 77:8745-8755. (Pubitemid 36936086)
25. Kollaritsch, H., M. Paulke-Korinek, and K. Dubischar-Kastner. 2009. IC51 Japanese encephalitis vaccine. Expert Opin. Biol. Ther. 9:921-931.
26. Konishi, E., and A. Fujii. 2002. Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine. Vaccine 20:1058-1067.
27. Konishi, E., A. Fujii, and P. W. Mason. 2001. Generation and characterization of a mammalian cell line continuously expressing Japanese encephalitis virus subviral particles. J. Virol. 75:2204-2212.
28. Konishi, E., A. Terazawa, and A. Fujii. 2003. Evidence for antigen production in muscles by dengue and Japanese encephalitis DNA vaccines and a relation to their immunogenicity in mice. Vaccine 21:3713-3720.
29. Konishi, E., I. Kurane, and P. W. Mason. 2000. Immune response to traditional and genetically engineered Japanese encephalitis vaccines. Recent Res. Dev. Virol. 2:1-21.
30. Konishi, E., K. Yagawa, and A. Yamanaka. 2008. Vero cells infected with vaccinia viruses expressing Japanese encephalitis virus envelope protein induce polykaryocyte formation under neutral conditions. Jpn. J. Infect. Dis. 61:410-411.
31. Konishi, E., M. Shoda, N. Ajiro, and T. Kondo. 2004. Development and evaluation of an enzyme-linked immunosorbent assay for quantifying antibodies to Japanese encephalitis virus nonstructural 1 protein to detect subclinical infections in vaccinated horses. J. Clin. Microbiol. 42:5087-5093.
32. Konishi, E., P. W. Mason, and R. E. Shope. 1996. Enzyme-linked immunosorbent assay using recombinant antigens for serodiagnosis of Japanese encephalitis. J. Med. Virol. 48:76-79.
33. Konishi, E., S. Pincus, E. Paoletti, R. E. Shope, T. Burrage, and P. W. Mason. 1992. Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection. Virology 188:714-720.
34. Kurane, I. 2002. Immune responses to Japanese encephalitis virus. Curr. Top. Microbiol. Immunol. 267:91-103.
35. Kuzuhara, S., H. Nakamura, K. Hayashida, J. Obata, M. Abe, K. Sonoda, K. Nishiyama, K. Sugawara, K. Takeda, T. Honda, H. Matsui, T. Shigaki, Y. Kino, H. Mizokami, M. Tanaka, K. Mizuno, and K. Ueda. 2003. Non-clinical and phase I clinical trials of a Vero cell-derived inactivated Japanese encephalitis vaccine. Vaccine 21:4519-4526.
36. Ledizet, M., K. Kar, H. G. Foellmer, T. Wang, S. L. Bushmich, J. F. Anderson, E. Fikrig, and R. A. Koski. 2005. A recombinant envelope protein vaccine against West Nile virus. Vaccine 23:3915-3924.
37. Lindenbach, B. D., H.-J. Thiel, and C. M. Rice. 2007. Flaviviridae: the viruses and their replication, p. 1101-1152. In D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Straus (ed.), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
38. Liu, W., H. Jiang, J. Zhou, X. Yang, Y. Tang, D. Fang, and L. Jiang. 2010. Recombinant dengue virus-like particles from Pichia pastoris: efficient production and immunological properties. Virus Genes 40:53-59.
39. Mackenzie, J. S. 2005. Emerging zoonotic encephalitis viruses: lessons from Southeast Asia and Oceania. J. Neurovirol. 11:434-440.
40. Mason, P. W., J. M. Dalrymple, M. K. Gentry, J. M. McCown, C. H. Hoke, D. D. Burke, M. J. Fournier, and T. L. Mason. 1989. Molecular characterization of a neutralizing domain of the Japanese encephalitis virus structural glycoprotein. J. Gen. Virol. 70:2037-2049.
41. Mason, P. W., S. Pincus, M. J. Fournier, T. L. Mason, R. E. Shope, and E. Paoletti. 1991. Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection. Virology 180:294-305.
42. McDonald, W. F., J. W. Huleatt, H. G. Foellmer, D. Hewitt, J. Tang, P. Desai, A. Price, A. Jacobs, V. N. Takahashi, Y. Huang, V. Nakaar, L. Alexopoulou, E. Fikrig, and T. J. Powell. 2007. A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity. J. Infect. Dis. 195: 1607-1617.
43. Mutoh, E., T. Ishikawa, A. Takamizawa, T. Kurata, T. Sata, and A. Kojima. 2004. Japanese encephalitis subunit vaccine composed of virus-like envelope antigen particles purified from serum-free medium of a high-producer J12#26 cell clone. Vaccine 22:2599-2608.
44. Oya, A., and I. Kurane. 2007. Japanese encephalitis for a reference to international travelers. J. Travel Med. 14:259-268. (Pubitemid 47041480)
45. Paavonen, J., D. Jenkins, F. X. Bosch, P. Naud, J. Salmerón, C. M. Wheeler, S. N. Chow, D. L. Apter, H. C. Kitchener, X. Castellsague, N. S. de Carvalho, S. R. Skinner, D. M. Harper, J. A. Hedrick, U. Jaisamrarn, G. A. Limson, M. Dionne, W. Quint, B. Spiessens, P. Peeters, F. Struyf, S. L. Wieting, M. O. Lehtinen, and G. Dubin; HPV PATRICIA study group. 2007. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369:2161-2170.
46. Pierson, T. C., and M. S. Diamond. 2008. Molecular mechanisms of antibody- mediated neutralisation of flavivirus infection. Expert Rev. Mol. Med. 10:e12.
47. Putnak, R., K. Porter, and C. Schmaljohn. 2003. DNA vaccines for flaviviruses. Adv. Virus. Res. 61:445-468.
48. Qiao, M., M. Ashok, K. A. Bernard, G. Palacios, Z. H. Zhou, W. I. Lipkin, and T. J. Liang. 2004. Induction of sterilizing immunity against West Nile Virus (WNV), by immunization with WNV-like particles produced in insect cells. J. Infect. Dis. 190:2104-2108.
49. Ravi, V., A. Desai, M. Balaji, M. P. Apte, L. Lakshman, D. K. Subbakrishna, G. Sridharan, T. N. Dhole, and B. V. Ravikumar. 2006. Development and evaluation of a rapid IgM capture ELISA (JEV-Chex) for the diagnosis of Japanese encephalitis. J. Clin. Virol. 35:429-434.
50. Shishido, T., M. Muraoka, H. Yamaji, A. Kondo, and H. Fukuda. 2007. Production of bionanocapsules in immobilized insect cell culture using porous biomass support particles. J. Biosci. Bioeng. 103:572-574.
51. Staropoli, I., M. P. Frenkiel, F. Mégret, and V. Deubel. 1997. Affinity-purified dengue-2 virus envelope glycoprotein induces neutralizing antibodies and protective immunity in mice. Vaccine 15:1946-1954.
52. Takahashi, H., N. Ohtaki, M. Maeda-Sato, M. Tanaka, K. Tanaka, H. Sawa, T. Ishikawa, A. Takamizawa, T. Takasaki, H. Hasegawa, T. Sata, W. W. Hall, T. Kurata, and A. Kojima. 2009. Effects of the number of amino acid residues in the signal segment upstream or downstream of the NS2B-3 cleavage site on production and secretion of prM/M-E virus-like particles of West Nile virus. Microbes Infect. 11:1019-1028.
53. Verma, R., E. Boleti, and A. J. George. 1998. Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems. J. Immunol. Methods 216:165-181.
54. Verma, S. K., S. Kumar, N. Gupta, S. Vedi, S. M. Bhattacharya, and P. V. Lakshmana Rao. 2009. Bacterially expressed recombinant envelope protein domain III of Japanese encephalitis virus (rJEV-DIII) elicits Th1 type of immune response in BALB/c mice. Vaccine 27:6905-6909.
55. Widman, D. G., I. Frolov, and P. W. Mason. 2008. Third-generation flavivirus vaccines based on single-cycle, encapsidation-defective viruses. Adv. Virus Res. 72:77-126.
56. Yang, D. K., C. H. Kweon, B. H. Kim, S. I. Lim, J. H. Kwon, S. H. Kim, J. Y. Song, and H. R. Han. 2005. Immunogenicity of baculovirus expressed recombinant proteins of Japanese encephalitis virus in mice. J. Vet. Sci. 6:125-133.
57. Zhang, Z. S., Y. S. Yan, Y. W. Weng, H. L. Huang, S. Q. Li, S. He, and J. M. Zhang. 2007. High-level expression of recombinant dengue virus type 2 envelope domain III protein and induction of neutralizing antibodies in BALB/c mice. J. Virol. Methods 143:125-131.